Comparable stake leader
L5 Capital Inc.
SEC ownership of HTG MOLECULAR DIAGNOSTICS, INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001169987.
Disclosed value leader
L5 Capital Inc.
Comparable rows
0/14
Latest evidence
08 Jun 2023
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
L5 Capital Inc.
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
08 Jun 2023
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001169987
- Issuer location
- Tucson, AZ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of HTG MOLECULAR DIAGNOSTICS, INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
L5 Capital Inc.
Disclosed value leader
L5 Capital Inc.
Comparable rows
0/14
Latest evidence
08 Jun 2023
3/4/5
Highest disclosed value: $936,000
14 rows are not safely comparable across share classes.
Showing 1-8 of 14 holder rows.
Quick read
L5 Capital Inc. has the largest disclosed position value at $936K.
0 of 14 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens L5 Capital Inc.'s linked filing trail.
Disclosed position value
Top 5
L5 Capital Inc.
$936K
John L. Lubniewski
$11.3K
Shaun D. McMeans
$8.5K
Byron Lawson
$4.8K
Laura Lee Godlewski
$3.9K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 14 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| L5 Capital Inc. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$936,000
1,170,000 shares
|
— | 15 Jul 2022 |
| John L. Lubniewski |
3/4/5
President & CEO, Director
|
—
class O/S missing
|
$11,306
14,133 shares
|
— | 09 Dec 2022 |
| Shaun D. McMeans |
3/4/5
SVP, Finance & Admin. & CFO
|
—
class O/S missing
|
$8,456
10,570 shares
|
— | 09 Dec 2022 |
| Byron Lawson |
3/4/5
SVP/Chief Commercial Officer
|
—
class O/S missing
|
$4,826
6,033 shares
|
— | 09 Dec 2022 |
| Laura Lee Godlewski |
3/4/5
SVP Finance & Administration
|
—
class O/S missing
|
$3,923
4,904 shares
|
— | 09 Dec 2022 |
| Stephen Barat |
3/4/5
Senior VP of Therapeutics
|
—
class O/S missing
|
$337
421 shares
|
— | 08 Jun 2023 |
| Ann Hanham |
3/4/5
Director
|
—
class O/S missing
|
—
8,000 shares
|
— | 15 Sep 2022 |
| Thomas W. Dubensky |
3/4/5
Director
|
—
class O/S missing
|
—
8,000 shares
|
— | 18 Aug 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-14 of 14 reporting-owner rows connected to HTG MOLECULAR DIAGNOSTICS, INC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
14
Largest Forms 3/4/5 holder
L5 Capital Inc.
Net 12M change
$0
Latest report
08 Jun 2023
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| L5 Capital Inc. | 10%+ Owner | $936,000 | Mixed | 15 Jul 2022 | ||
| John L. Lubniewski | President & CEO, Director | $11,306 | Mixed | 09 Dec 2022 | ||
| Shaun D. McMeans | SVP, Finance & Admin. & CFO | $8,456 | Mixed | 09 Dec 2022 | ||
| Byron Lawson | SVP/Chief Commercial Officer | $4,826 | Mixed | 09 Dec 2022 | ||
| Laura Lee Godlewski | SVP Finance & Administration | $3,923 | Mixed | 09 Dec 2022 | ||
| Stephen Barat | Senior VP of Therapeutics | $337 | Filing P/S | 08 Jun 2023 | ||
| Lee R. McCracken | Director | Mixed | 15 Sep 2022 | |||
| Ann Hanham | Director | Mixed | 15 Sep 2022 | |||
| Christopher P. Kiritsy | Director | Mixed | 15 Sep 2022 | |||
| Don M. Hardison | Director | Mixed | 15 Sep 2022 | |||
| Thomas W. Dubensky | Director | Mixed | 18 Aug 2022 | |||
| Harry A. George | Director | Mixed | 18 Aug 2021 | |||
| James T. LaFrance | Director | Mixed | 18 Aug 2021 | |||
| Michelle Renee Griffin | Director | Mixed | 15 Sep 2022 |
Recent insider transactions for HTG MOLECULAR DIAGNOSTICS, INC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.